Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Amicus Therapeutics Inc. buy tamam

Start price
€13.67
24.05.18 / 50%
Target price
€23.00
04.11.21
Performance (%)
-22.43%
End price
€10.60
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €10.60. The price of Amicus Therapeutics Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -22.43%. tamam has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Amicus Therapeutics Inc. 2.804% 2.804% 7.129% 34.969%
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

Comments by tamam for this prediction

In the thread Amicus Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -22.43%
Target price 29.766
Change
Ends at 04.11.21

Amicus verfügt über eine Entwicklungspipeline mit neuartigen „First-in-Class-Behandlungen“



The firm has one of the best management teams (especially CEO John Crowley) of the companies on my radar, a near term regulatory update for their Pompe program could move the stock significantly in the event of accelerated approval pathway, the Galafold launch (and possible approval in the US) are also upside drivers and after their February secondary offering they have a comfortable cash position.



Prediction Buy
Perf. (%) -22.43%
Target price 19.766
Change
Ends at 04.11.21

Kursziel geändert auf 19,766

Prediction Buy
Perf. (%) -22.43%
Target price 13.766
Change
Ends at 04.11.21

Kursziel geändert auf 13,766

Prediction Buy
Perf. (%) -22.43%
Target price 16.000
Change
Ends at 04.11.21

Kursziel geändert auf 16,0

Prediction Buy
Perf. (%) -22.43%
Target price 23.000
Change
Ends at 04.11.21

Kursziel geändert auf 23,0

In the thread Trading Amicus Therapeutics Inc.
Prediction Buy
Perf. (%) -22.43%
Target price 23.000
Change
Ends at 04.11.21

Die von tamam gewählte maximale Laufzeit wurde überschritten